The purpose of this study is to find the highest doses of two investigational drugs, tremelimumab and MEDI4736, when given together in patients with stage IIIB or IV non-small cell lung cancer that has returned despite standard therapy, has stopped responding to standard therapy, or (by patient’s choice) is not being treated with standard therapy.
Tremelimumab is an antibody that blocks cytotoxic T lymphocyte antigen 4 (CTLA4), a protein found on cells of the immune system. CTLA4 puts the brakes on the immune response and may prevent immune cells from attacking cancer cells. Tremelimumab prevents this from happening, potentially enhancing the immune response against the cancer.
MEDI4736 is an antibody designed to boost the body’s immune system by targeting a protein on tumor cells called PD-L1. PD-L1 normally maintains the balance of the immune system. In cancer, PD-L1 helps tumors evade detection and elimination by the immune system. MEDI4736 may increase the immune system’s ability to identify and destroy cancer cells.
Both drugs are given intravenously (by vein).